- Home
- NECB vs YMAB Comparison
NECB vs YMAB Comparison
Compare NECB & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NECB
- YMAB
- Stock Information
- Founded
- NECB 1934
- YMAB 2015
- Country
- NECB United States
- YMAB United States
- Employees
- NECB N/A
- YMAB N/A
- Industry
- NECB Savings Institutions
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- NECB Finance
- YMAB Health Care
- Exchange
- NECB Nasdaq
- YMAB Nasdaq
- Market Cap
- NECB 263.6M
- YMAB 218.4M
- IPO Year
- NECB N/A
- YMAB 2018
- Fundamental
- Price
- NECB $23.65
- YMAB $4.04
- Analyst Decision
- NECB
- YMAB Buy
- Analyst Count
- NECB 0
- YMAB 11
- Target Price
- NECB N/A
- YMAB $18.73
- AVG Volume (30 Days)
- NECB 38.3K
- YMAB 204.4K
- Earning Date
- NECB 04-21-2025
- YMAB 05-13-2025
- Dividend Yield
- NECB 3.15%
- YMAB N/A
- EPS Growth
- NECB 0.72
- YMAB N/A
- EPS
- NECB 3.44
- YMAB N/A
- Revenue
- NECB $104,392,000.00
- YMAB $87,685,000.00
- Revenue This Year
- NECB $2.80
- YMAB N/A
- Revenue Next Year
- NECB $8.34
- YMAB $18.83
- P/E Ratio
- NECB $6.70
- YMAB N/A
- Revenue Growth
- NECB 2.77
- YMAB 3.38
- 52 Week Low
- NECB $16.51
- YMAB $3.84
- 52 Week High
- NECB $31.72
- YMAB $17.47
- Technical
- Relative Strength Index (RSI)
- NECB 60.97
- YMAB 42.87
- Support Level
- NECB $22.85
- YMAB $4.02
- Resistance Level
- NECB $23.95
- YMAB $4.60
- Average True Range (ATR)
- NECB 0.79
- YMAB 0.32
- MACD
- NECB 0.17
- YMAB -0.01
- Stochastic Oscillator
- NECB 90.68
- YMAB 23.93
About NECB NorthEast Community Bancorp Inc.
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.